Tiltan Pharma

About:

One of the major advances in cancer research over the past decade has been the realization that tumor growth is dependent on the tumor's

Website: http://tiltanpharma.com

Description:

One of the major advances in cancer research over the past decade has been the realization that tumor growth is dependent on the tumor's ability to recruit blood vessels from the neighboring tissue. Angiogenesis, the process by which new blood vessels are formed, is a hallmark capability of cancer, critical for the development of all solid tumors. This property is the basis for anti-angiogenic therapy, a promising novel strategy for treatment of cancer.

Total Funding Amount:

$1.5M

Headquarters Location:

Jerusalem, Yerushalayim, Israel

Founded Date:

2006-01-01

Contact Email:

info(AT)tiltanpharma.com

Founders:

Yigal Stav

Number of Employees:

1-10

Last Funding Date:

2014-02-05

IPO Status:

Private

Industries:

© 2025 bioDAO.ai